What is ACRS's dilution risk score?

ACRS has a latest available DilutionScore record of 65/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for ACRS, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for ACRS?

DilutionWatch tracks 25 SEC filing types for ACRS including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect ACRS shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For ACRS, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for ACRS tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for ACRS. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

ACRS Dilution Risk Score: 65/100 (HIGH)

Score Breakdown

📋 Offering Ability

52

💰 Cash Runway

95

📊 Float Risk

22

⚠️ Warrant Exposure

40

🔄 Convertible Debt

40

Dilution Forecast

🌥️

Advisory

Moderate dilution signals present

model est. 34%

💰 Capital Raise model 55%

• Critical: only 2.9 months cash remaining

🔄 Reverse Split model est. 15%

• Only 3 months cash — financial pressure

📉 Score Deterioration model 10%

• Score in HIGH risk zone (65/100)

🔔 Track ACRS — Get forecast alerts →

Market Data

Market Cap$635.47M

Shares Outstanding147.20M

Float113.21M

Cash$19.17M

Debt$10.73M

Short InterestN/A

Institutional Holdings

QoQ: ↑ 53.1% shares (2026Q1 vs prior)

139 institutional holders · 134.20M shares

#1 BML Capital Management, LLC 14.25M shares

#2 Vivo Capital, LLC 13.33M shares

#3 VANGUARD CAPITAL MANAGEMENT LLC 10.33M shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest13.77M

Days to Cover8.7

% of Float12.2%

FINRA data as of Jul 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2024-12-31

xbrl XBRL CONVERTIBLE 2023-12-31

4 INSIDER TRANSACTION 2026-04-27

8-K 8K EVENT 2026-03-11

8-K 8K EVENT 2026-03-10

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual ACRS Dilution Snapshot

Aclaris Therapeutics, Inc. (ACRS) has a DilutionScore of 65/100, rated High dilution risk. Score date: August 28, 2026.

Recent SEC activity tracked for ACRS: 4 on 2026-04-27; 8-K on 2026-03-11; 8-K on 2026-03-10.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.